COVID-19 Virtual Partnering
MedPharm recognises that continuous collaboration is vital during these unprecedented times in finding a solution against COVID-19 and our scientists have been working hard behind the scenes to support the cause.
To accelerate global alliances, COVID-19 Virtual Partnering has been created to connect leaders across all industries together, to partner against COVID-19. Connect with our MedPharm representatives on the One-to-One Partnering system to learn how we’ve advanced our bespoke nasal, airways and deep lung tissue models to help companies’ de-risk and accelerate their drug product development timelines.
MedPharm, a leading clinical development organization in topical and transdermal drug delivery, has expanded its innovative testing models to support pharmaceutical development programmes targeting Coronavirus treatments. These models allow companies to assess therapeutic effectiveness in nasal, airway (bronchial), and deep lung (alveolar) epithelia against members of the Coronaviridae family. The work will help to de-risk development programs and screen drugs for therapeutic effectiveness to accelerate development prior to clinical trials.